Pulike Biological Engineering

Pulike Biological Engineering Net Margin

The Net Profit Margin of Pulike Biological Engineering (603566.SS) as of Oct 17, 2026 is 16.97 %. In the previous year, Net Profit Margin was 8.90 % — a change of 90.68% (higher).

Net Margin

16.97 %

YoY

90.68%

Last updated:

Net Profit Margin of Pulike Biological Engineering is 2025 16.97 % . Net Profit Margin of Pulike Biological Engineering was 2024 8.90 % . It decreases by 90.68% higher compared to the previous year.

Pulike Biological Engineering's net margin stands at 17.0%, down from 22.2% several years earlier.

The Pulike Biological Engineering Net Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Margin
Date
Net Margin
Jan 1, 2018
22.30 CNY
Jan 1, 2019
16.47 CNY
Jan 1, 2020
23.33 CNY
Jan 1, 2021
22.22 CNY
Jan 1, 2022
13.64 CNY
Jan 1, 2023
13.93 CNY
Jan 1, 2024
8.90 CNY
Jan 1, 2025
16.97 CNY
The Pulike Biological Engineering Net Margin history
YEARNet MarginYoY
16.97 %+90.68%
8.90 %-36.10%
13.93 %+2.11%
13.64 %-38.61%
22.22 %-4.76%
23.33 %+41.65%
16.47 %-26.14%
22.30 %+3.50%
21.55 %-33.16%
32.24 %+8.76%
29.64 %+0.54%
29.48 %+8,446.69%
0.34 %+11.48%
0.31 %+10.68%
0.28 %-2.67%
0.29 %-17.48%
0.35 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Pulike Biological Engineering Stock analysis

What does Pulike Biological Engineering do? Pulike Biological Engineering Inc, listed on the Shanghai Stock Exchange with ticker 603566.SS and ISIN CNE1000025N0, is a pharmaceutical company based in Luoyang, China. The company went public on May 18, 2015. It employs 1,718 people and operates within the healthcare sector, specifically in the pharmaceuticals industry. Pulike Biological Engineering focuses on the research, development, manufacturing, and sale of biological products for animals, chemical drugs, and Chinese veterinary drugs. The company's veterinary biological products include vaccines and antibodies, which are used for the prevention and control of infectious diseases in poultry and livestock. Its veterinary chemical medicines are primarily used for treating epidemic diseases affecting poultry and livestock. The company is headquartered in Luoyang, Henan, and its website is http://www.pulike.com.cn/. Pulike Biological Engineering Inc is engaged in the research, development, production, and distribution of veterinary biological products and chemical medicines. The firm's product portfolio targets the prevention and treatment of diseases in animals, with a focus on poultry and livestock health management. Pulike Biological Engineering is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Pulike Biological Engineering stock

Net Profit Margin of Pulike Biological Engineering is 16.97 % in 2025.

Net Profit Margin of Pulike Biological Engineering changed from 8.90 % to 16.97 %, representing a 90.68% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Profit Margin Pulike Biological Engineering since 2006 – with annual values, charts, and detailed analysis.

Net Margin measures the percentage of revenue that becomes net profit after all expenses. It is the ultimate measure of a company's profitability.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Profit Margin's Pulike Biological Engineering with sector peers and the industry average to assess whether it is attractive.

To evaluate Net Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Net Profit Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Margins — Pulike Biological Engineering

Gross MarginEBIT MarginEBITDA MarginNet MarginFCF MarginR&D / RevenueTax RatePayout RatioPre-Tax MarginOCF MarginSGA/RevenueOpEx/RevenueReinvestment Rate

All Key Metrics — Pulike Biological Engineering